Prevention and Early Identification for High Risk Youth in School-based Clinics

Sponsor
Cambridge Health Alliance (Other)
Overall Status
Recruiting
CT.gov ID
NCT04935710
Collaborator
National Institute of Mental Health (NIMH) (NIH)
108
4
2
30.9
27
0.9

Study Details

Study Description

Brief Summary

The proposed research project provides a novel approach to screening, early assessment, and preventive interventions for high-risk youth in racial/ethnic/linguistically (REL)-diverse communities.

  • The investigators assess a health promotion intervention as a way of reducing treatment disparities in REL-minority youth. This population is underrepresented in child psychiatry research. It is often excluded from clinical trials of medication or therapy because of challenges with transportation, literacy, resources or other issues.

  • The study will take place during or following a health care crisis and economic recession, making findings relevant to understanding the mechanisms by which hardship translates into youth mental illness.

  • The innovative integration of online screening into school-based clinics in REL-minority communities is made possible by the combination of access to a new technology (CAT) in the context of a learning health community serving an REL-minority population.

  • Empirical research on the impact of a resilience-based prevention intervention in youth and youth at risk is both innovative and much needed during this period of health, social and economic crisis.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: COPE2Thrive
  • Genetic: Usual care
Phase 1

Detailed Description

Four hundred students will be screened for psychiatric symptoms and functional impairment using the Kiddie Computerized Adaptive Testing (K-CAT) and the Weiss Functional Impairment Rating Scale - Self Report (WFIRS-S) at the school-based teen health centers in Cambridge, Everett, and Somerville. Students will be classified into three tiers: normal, at risk, and clinical . The cut off scores that differentiate the tiers are drawn from the ROC values generated by the psychometrics of the measures themselves as follows:

Tier 1: K-CAT Normal & WFIRS <0.8 - >1.0 (T <1SD). Tier 2: K-CAT Mild & WFIRS 0.8 - >1.0, K-CAT Moderate & WFIRS 0.8 - 1.0 (T between 1 and 1.5 SD), K-CAT Severe & WFIRS 0.8 - 1.0 (T between 1 and 1.5 SD) Tier 3: K-CAT Moderate & WFIRS >1.0 (T >1.5 SD), K-CAT Severe & WFIRS

1.0 (T >1.5 SD) If patients are symptomatic but not functionally impaired, status is determined by function because symptoms without impairment do not necessarily warrant intervention. If the patient is impaired but not symptomatic, the threshold is determined by symptoms because the patient may be impaired from factors other than the diagnosis. These scores are based on the results of the most severe module of either the K-CAT or the WFIRS. Tier 1 will receive usual school services as needed. Tier 2 students will be given the option to participate in the resilience-building COPE2Thrive (C2T) intervention. Tier 3 will be informed that the participants' responses suggest that the participants are experiencing some symptoms which are causing them difficulty. As long as the participants are not assessed as critical imminent risk, Tier 3 will also be invited to participate in C2T.

A stepped wedge design with 3 clusters of 36 students each will be used to group students into clusters based on rolling recruitment into COPE2Thrive. The stepped wedge design assigns a random cluster to be switched from the control group to the C2T intervention group at 1, 2, and 3-month intervals starting in January 2022.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
108 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Prevention and Early Identification for High Risk Youth in School-based Clinics (ALACRITY eSToRY R34 #1)
Actual Study Start Date :
Jan 3, 2022
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Aug 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: R34#1 Aim 2 COPE2Thrive Intervention

Youth identified as being at risk but without a major mental health disorder will be randomized to receive a resilience based digital intervention, COPE2Thrive.

Behavioral: COPE2Thrive
Cognitive Behavioral Therapy-based program to help teens deal with anxiety, stress and depression by showing them how to develop skills needed to stop negative thoughts and start thinking and behaving in more positive ways.

Active Comparator: Control arm

The comparator arm is treatment as usual. For each monthly crossover, 12 students in a cluster are eligible to receive C2T in a stepped wedge study design. Student outcomes prior to receiving C2T will be compared to outcomes after receiving C2T.

Genetic: Usual care
Children at risk who are not randomized to COPE2Thrive at any point of time serve as the control group.
Other Names:
  • No intervention
  • Outcome Measures

    Primary Outcome Measures

    1. Kiddie Computerized Adaptive Testing Self Report (K-CAT-S) [3 months or time to completion of the COPE2T intervention]

      The K-CAT-S is a computerized adaptive test for assessment of DSM 5 conditions in youth. Adaptive testing allows the assessment to be done in less than 10 minutes with high validity compared against diagnostic interviews. High scores indicate greater psychopathology. The minimum score is 0, a score between 45-64 is moderate, a score greater than 65 is severe, and the maximum score is 100. Change in the numeric level of these symptoms will be the primary outcome of the testing of the preliminary effectiveness of the COPE2Thrive intervention.

    Secondary Outcome Measures

    1. Weiss Functional Impairment Rating Scale - Self Report (WFIRS-S) [3 months or time to completion of the COPE2Thrive intervention]

      The Weiss Functional Impairment Scale Self Report (WFIRS-S) is an assessment of the student's perception of the participant's functional impairment over the past month, across six domains including family, school, life skills, child's self-concept, social activities, and risky activities. Higher mean item scores indicate greater functional impairment. The minimum mean item score is 0, the maximum mean item score is 3, and the ROC population cut-off is 0.65. A mean change score of 0.25 is the minimal clinical important difference.

    2. Kiddie Computerized Adaptive Testing Parent Report(K-CAT-P) [3 months or time to completion of the COPE2Thrive intervention]

      The Kiddie Computerized Adaptive Testing (K-CAT-P) will be administered to parents to obtain collateral parent report of youth symptoms. The scoring metrics of this testing are identical to the Kiddie Computerized Adaptive Testing Student Report (K-CAT-S) reported above. The Kiddie Computerized Adaptive Testing Parent Report (K-CAT-P) screener provides a combined numeric score for each module based on validated quantitative comparisons. Higher scores indicate higher levels of symptoms. The minimum score for any module is 0, a numeric score between 45-64 for any module is considered moderate, a numeric score of 65 or above for any module is considered severe, and the maximum score for any module is 100.The K-CAT-P includes a total of 6 modules, so the maximum total score for the assessment is 600.

    3. Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) [3 months or time to completion of the COPE2Thrive intervention]

      The Weiss Functional Impairment Scale Parent Report (WFIRS-P) is an assessment of the parent's perception of the child's functional impairment over the past month, across six domains including family, school learning and behavior, life skills, child's self-concept, social activities, and risky activities. Higher mean item scores indicate greater functional impairment. The minimum mean item score is 0, the maximum mean item score is 3, and the ROC population cut-off is 0.65. A mean change score of 0.25 is the minimal clinical important difference.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    12 Years to 21 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria for COPE2 Thrive:
    • Youth attend a high school in which there is a CHA school teen health center

    • Youth who are fluent in English, Haitian-Creole, Portuguese, or Spanish.

    • Youth who experience at least some symptoms defined as a K-CAT-S score of moderate on at least one diagnosis with at least mild functional impairment. Patients with more severe symptoms or functional impairment or do not meet the exclusion criteria are also eligible.

    Exclusion Criteria:
    • 12th-graders will be excluded from the COPE2Thrive program since the participants will not be available for the study's duration

    • Students who are already receiving behavioral health care.

    • Students who are considered to be seriously suicidal and in need of urgent care, in which case the participants would be ineligible based on the fact that the participants will be receiving behavioral health care.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 CHA-Teen Health Center at Cambridge Rindge and Latin School Cambridge Massachusetts United States 02138-4125
    2 CHA Health Equity Research Lab Cambridge Massachusetts United States 02141-1047
    3 CHA Teen Health Center at Everett High School Everett Massachusetts United States 02149-5128
    4 CHA Teen Connections at Somerville High School Somerville Massachusetts United States 02143-1740

    Sponsors and Collaborators

    • Cambridge Health Alliance
    • National Institute of Mental Health (NIMH)

    Investigators

    • Study Chair: Benjamin Cook, PhD, Health Equity Research Lab

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Margaret D Weiss, MD PhD, Principal Investigator, Cambridge Health Alliance
    ClinicalTrials.gov Identifier:
    NCT04935710
    Other Study ID Numbers:
    • ALACRITY eSToRY R34 #1
    • P50MH126283
    First Posted:
    Jun 23, 2021
    Last Update Posted:
    May 12, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Margaret D Weiss, MD PhD, Principal Investigator, Cambridge Health Alliance

    Study Results

    No Results Posted as of May 12, 2022